Polymorphisms in the Promoter Region of the Basic Fibroblast Growth Factor Gene Are Not Associated with Myocardial Infarction in a Slovene Population with Type 2 Diabetes

Abstract

Basic fibroblast growth factor (bFGF) is a multifunctional growth factor that may play a significant role in atherosclerotic vascular complications in patients with type 2 diabetes. This study was designed to investigate the association between genetic polymorphisms (–553 T/A, −834 T/A and −921 C/G) in the promoter region of the bFGF gene and myocardial infarction (MI) in 443 patients with type 2 diabetes (149 with MI and 294 with no history of coronary artery disease). The −553 T/A, −834 T/A and −921 C/G polymorphisms of the bFGF gene were found not to be risk factors for MI in patients with type 2 diabetes. The impact of bFGF gene polymorphisms on serum bFGF levels was also investigated and significantly higher serum levels of bFGF were demonstrated in diabetes patients with the TA genotype of the −553 T/A polymorphism compared with diabetes patients with the TT wild type genotype (9.0 ± 5.6 ng/l versus 3.0 ± 1.9 ng/l, respectively). Thus, the tested bFGF gene polymorphisms cannot be used as genetic markers for MI in diabetic Caucasians.

Keywords

Type 2 diabetes mellitus Myocardial infarction Promoter region Polymorphisms

References

Moreno

Fuster

: New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004; 44: 2293–2300.

Flugelman

Virmani

Correa

: Smooth muscle cell abundance and fibroblast growth factors in coronary lesions of patients with nonfatal unstable angina. A clue to the mechanism of transformation from the stable to the unstable clinical state. Circulation 1993; 88: 2493–2500.

Brogi

Winkles

Underwood

: Distinct patterns of expression of fibroblast growth factors and their receptors in human atheroma and nonatherosclerotic arteries. Association of acidic FGF with plaque microvessels and macrophages. J Clin Invest 1993; 92: 2408–2418.

Kumar

West

Shahabuddin

: Angiogenesis factor from human myocardial infarcts. Lancet 1983; 322: 364–368.

Casscells

Speir

Sasse

: Isolation, characterization, and localization of heparin-binding growth factors in the heart. J Clin Invest 1990; 85: 433–441.

Hughes

Crossman

Hall

: Expression of basic and acidic fibroblast growth factors and their receptor in normal and atherosclerotic human arteries. Cardiovasc Res 1993; 27: 1214–1219.

Hughes

: Localisation and differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal and atherosclerotic human arteries. Cardiovasc Res 1996; 32: 557–569.

Teshima-Kondo

Kondo

Lourenco

L Prado

: Hyperglycemia upregulates translation of the fibroblast growth factor 2 mRNA in mouse aorta via internal ribosome entry site. FASEB J 2004; 18: 1583–1585.

Karpen

Spanheimer

Randolph

: Tissue-specific regulation of basic fibroblast growth factor mRNA levels by diabetes. Diabetes 1992; 41: 222–226.

10.

Panutsopulos

Zafiropoulos

Krambovitis

: Peripheral monocytes from diabetic patients with coronary artery disease display increased bFGF and VEGF mRNA expression. J Transl Med 2003; 1: 6.

11.

Lafage-Pochitaloff

Galland

Simonetti

: The human basic fibroblast growth factor gene is located on the long arm of chromosome 4 at bands q26–q27. Oncogene Res 1990; 5: 241–244.

12.

Beranek

Tschoplova

Kankova

: Genetic variation in the promoter region of the basic fibroblast growth factor gene. Hum Immunol 2003; 64: 374–377.

13.

Alpert

Thygesen

Antman

: Myocardial infarction redefined–a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959–969.

14.

Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003; 26 (suppl 1): S5–S20.

15.

Araki

Shimada

Kaji

: Apoptosis of vascular endothelial cells by fibroblast growth factor deprivation. Biochem Biophys Res Commun 1990; 168: 1194–1200.

16.

Terranova

DiFlorio

Lyall

: Human endothelial cells are chemotactic to endothelial cell growth factor and heparin. J Cell Biol 1985; 101: 2330–2334.

17.

Klein

Roghani

Rifkin

: Fibroblast growth factors as angiogenesis factors: New insights into their mechanism of action. EXS 1997; 79: 159–192.

18.

Lappalainen

Laine

Pentikainen

: Mast cells in neovascularized human coronary plaques store and secrete basic fibroblast growth factor, a potent angiogenic mediator. Arterioscler Thromb Vasc Biol 2004; 24: 1880–1885.

19.

Zimering

Eng

: Increased basic fibroblast growth factor-like substance in plasma from a subset of middle-aged or elderly male diabetic patients with microalbuminuria or proteinuria. J Clin Endocrinol Metab 1996; 81: 4446–4452.

20.

McClain

Paterson

Roos

: Glucose and glucosamine regulate growth factor gene expression in vascular smooth muscle cells. Proc Natl Acad Sci USA 1992; 89: 8150–8154.

21.

Schulz

Kohler

Schagdarsurengin

: The human FGF2 level is influenced by genetic predisposition. Int J Cardiol 2005; 101: 265–271.

22.

Beranek

Kolar

Tschoplova

: Genetic variation and plasma level of the basic fibroblast growth factor in proliferative diabetic retinopathy. Diabetes Res Clin Pract 2008; 79: 362–367.

23.

Petrovic

Krkovic

Osredkar

: Polymorphisms in the promoter region of the basic fibroblast growth factor gene and proliferative diabetic retinopathy in Caucasians with type 2 diabetes. Clin Experiment Ophthalmol 2008; 36: 168–172.

24.

Targher

Bertolini

Zenari

: Diabetic retinopathy is associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabet Med 2008; 25: 45–50.

25.

Juutilainen

Lehto

Rönnemaa

: Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. Diabetes Care 2007; 30: 292–299.

26.

Haffner

: Coronary heart disease in patients with diabetes. N Engl J Med 2000; 342: 1040–1042.

27.

Bacci

Villella

: Screening for silent myocardial ischaemia in type 2 diabetic patients with additional atherogenic risk factors: Applicability and accuracy of the exercise stress test. Eur J Endocrinol 2002; 147: 649–654.